Dudley Lamming, Ph.D. is an Assistant Professor in the Division of Endocrinology, Diabetes and Metabolism at the University of Wisconsin-Madison School of Medicine and Public Health. He received his bachelor’s degree in Nuclear Engineering from the Massachusetts Institute of Technology, and his Ph.D. in Experimental Pathology from Harvard University. While at Harvard, he studied the biology of aging using yeast as a model system in the laboratory of David Sinclair. Dr. Lamming then joined the laboratory of David Sabatini at the Whitehead Institute of Biomedical Research, where he transitioned to studying the biology of aging in mammalian model systems.
The Lamming laboratory is primarily focused on understanding the physiological role played by the mechanistic target of rapamycin (mTOR), a protein kinase that, through a diverse set of substrates, regulates cellular processes including growth, metabolism, and aging. Recent work has shown that rapamycin, an inhibitor of mTOR signaling, can promote health and longevity in model organisms including mammals. As detailed by Dr. Lamming in a recent review article – Rapalogs and mTOR inhibitors as anti-aging therapeutics – understanding and manipulating the mTOR signaling pathway may provide insight into the treatment of age-related diseases, including diabetes, Alzheimer’s disease, and cancer.
The Lamming laboratory is particularly interested in understanding the role played by mTOR complex 2 (mTORC2) in the regulation of glucose homeostasis and longevity. Dr. Lamming’s research has been supported by the NIH National Institute on Aging, the American Federation for Aging Research (AFAR), and the American Diabetes Association.